Pages that link to "Q46428506"

The following pages link to A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. (Q46428506):

Displaying 34 items.

• Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia (Q24203027) (← links)
• Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia (Q26781895) (← links)
• Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment (Q28082086) (← links)
• The biology behind PI3K inhibition in chronic lymphocytic leukaemia (Q28083266) (← links)
• The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation (Q33816583) (← links)
• Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals (Q34184717) (← links)
• B-cell receptor signaling as a driver of lymphoma development and evolution (Q34398579) (← links)
• Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium (Q34488779) (← links)
• Therapeutic advancement of chronic lymphocytic leukemia (Q36300303) (← links)
• Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL (Q36404778) (← links)
• Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications (Q36862781) (← links)
• Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives (Q37132788) (← links)
• Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies (Q37432231) (← links)
• Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies (Q37598141) (← links)
• Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies (Q37779489) (← links)
• Post-transplant lymphoproliferative disorders following solid-organ transplantation (Q37810068) (← links)
• Temsirolimus for the treatment of mantle cell lymphoma (Q37810084) (← links)
• Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma (Q37823019) (← links)
• Mammalian target of rapamycin as a target in hematological malignancies (Q37866136) (← links)
• Aberrantly activated anti‐apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets (Q37866334) (← links)
• Chronic lymphocytic leukemia: an update on biology and treatment. (Q37902948) (← links)
• Signal transduction inhibitors in chronic lymphocytic leukemia (Q37926448) (← links)
• mTOR kinase inhibitors as a treatment strategy in hematological malignancies (Q37993588) (← links)
• Targeting the B cell receptor pathway in chronic lymphocytic leukemia (Q38012179) (← links)
• Research and innovation in the development of everolimus for oncology. (Q38014589) (← links)
• Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment (Q38110472) (← links)
• Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. (Q38212951) (← links)
• RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia (Q38872127) (← links)
• Study on the function and mechanism of atorvastatin in regulating leukemic cell apoptosis by the PI3K/Akt pathway. (Q41042432) (← links)
• Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma (Q41241688) (← links)
• Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia (Q42432648) (← links)
• Current and emerging treatments for chronic lymphocytic leukaemia (Q43242768) (← links)
• Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. (Q44638649) (← links)
• Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. (Q54704847) (← links)